Form 4: Akebia Therapeutics SVP, CFO, CBO & Treasurer Erik Ostrowski Reports Stock and Option Grants

Erik Ostrowski, SVP, CFO, CBO & Treasurer of Akebia Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• On January 31, 2025, Erik Ostrowski, SVP, CFO, CBO & Treasurer of Akebia Therapeutics, acquired 194,900 shares of common stock in the form of restricted stock units and 292,300 stock options.
• The restricted stock units vest in three equal annual installments starting on the first anniversary of the grant date.
• The stock options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal quarterly installments thereafter.
• Following these transactions, Ostrowski beneficially owns 544,900 shares of common stock and 292,300 stock options.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive signal.

Positives

• The grant of restricted stock units and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued service and contribution from the executive.

Industry Context

Equity grants are a common practice in the biotechnology industry to incentivize and retain key executives. The vesting schedules are typical for such grants.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard compensation practices in the biotech industry.
• Vesting schedules of 3-4 years are typical to align executive incentives with long-term company performance.
• Comparable companies like BioCryst Pharmaceuticals or Global Blood Therapeutics also utilize similar equity-based compensation plans.

Stakeholder Impact

• The equity grants align management's interests with shareholders, potentially driving long-term value creation.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates